Ultragenyx Pharmaceutical Inc. (RARE): EBITDA
-$500.00M
Year ended 2025-12-31
| Period ended | EBITDA | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$500.00M | n/m | 2026-02-18, From 2025-01-01 |
| 2024-12-31 | -$500.00M | n/m | 2026-02-18, From 2024-01-01 |
| 2023-12-31 | -$543.00M | n/m | 2026-02-18, From 2023-01-01 |
| 2022-12-31 | -$630.70M | n/m | 2025-02-19, From 2022-01-01 |
| 2021-12-31 | -$368.50M | n/m | 2024-02-21, From 2021-01-01 |
| 2020-12-31 | -$317.86M | n/m | 2023-02-17, From 2020-01-01 |
| 2019-12-31 | -$415.63M | n/m | 2022-02-15, From 2019-01-01 |
| 2018-12-31 | -$351.83M | n/m | 2021-02-12, From 2018-01-01 |
| 2017-12-31 | -$323.12M | n/m | 2020-02-14, From 2017-01-01 |
| 2016-12-31 | -$244.58M | n/m | 2019-02-20, From 2016-01-01 |
| 2015-12-31 | -$146.35M | n/m | 2018-02-21, From 2015-01-01 |
| 2014-12-31 | -$56.09M | n/m | 2017-02-17, From 2014-01-01 |
| 2013-12-31 | -$31.84M | n/m | 2016-02-26, From 2013-01-01 |
| 2012-12-31 | -$15.67M | n/a | 2015-03-27, From 2012-01-01 |
EBITDA at similar companies
| Company | Year ended | EBITDA | Change YoY |
|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. (RARE) | 2025-12-31 | -$500.00M | n/m |
| Kiniksa Pharmaceuticals International, plc (KNSA) | 2025-12-31 | $78.78M | n/m |
| Supernus Pharmaceuticals, Inc. (SUPN) | 2025-12-31 | $29.28M | -81.9% |
| Pacira BioSciences, Inc. (PCRX) | 2025-12-31 | $110.21M | n/m |
| TG Therapeutics, Inc. (TGTX) | 2025-12-31 | $123.38M | +193.8% |
| Emergent BioSolutions Inc. (EBS) | 2025-12-31 | $195.90M | n/m |
| Opko Health, Inc. (OPK) | 2025-12-31 | -$25.78M | n/m |
| Corcept Therapeutics Inc (CORT) | 2025-12-31 | $45.95M | -66.6% |
| Organogenesis Holdings Inc. (ORGO) | 2025-12-31 | $59.97M | +386.0% |
Compare RARE, KNSA, SUPN, PCRX side by side · Screen every company in Pharmaceutical Preparations ↗